

Review Article

Statin Use Is Associated with Better Prognosis of Patients with Prostate Cancer after Definite Therapies: A Systematic Review and Meta-Analysis of Cohort Studies

Ye An (b, Jian-Xuan Sun (b, Meng-Yao Xu (b, Chen-Qian Liu (b, Jin-Zhou Xu (b, Xing-Yu Zhong (b, Jia Hu (b, Qi-Dong Xia (b, Heng-Long Hu (b, and Shao-Gang Wang (b)

Department and Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1095 Jiefang Avenue, Wuhan 430030, China

Correspondence should be addressed to Qi-Dong Xia; qidongxia_md@163.com, Heng-Long Hu; huhenglong@hust.edu.cn, and Shao-Gang Wang; sgwangtjm@163.com

Received 16 August 2022; Revised 28 October 2022; Accepted 1 November 2022; Published 15 November 2022

Academic Editor: Han Han

Copyright © 2022 Ye An et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. Although the prognostic effect of statins on patients with prostate cancer (PCa) has been frequently evaluated, a consistent result is still lacking. We aimed to evaluate the association between statin use and mortality among patients with PCa after definite therapies. *Methods.* A systematic search of PubMed and other databases for cohort studies about the effect of statins on patients with PCa was performed until April 2022. Meta-analysis was performed using R software version 4.1.2. *Results.* 24 cohort studies involving 369, 206 participants were finally included. We found statin use significantly reduced the risk of prostate cancer-specific mortality (PCSM) with a pooled hazard ratio (pHR) = 0.76 (95% CI: 0.69–0.84, 18 studies), especially for postdiagnostic statin users: pHR = 0.81 (95% CI: 0.77–0.85) and patients who accepted androgen deprivation therapy (ADT): pHR = 0.69 (95% CI: 0.68–0.85, 17 studies), especially for postdiagnostic statin users: pHR = 0.71 (95% CI: 0.63–0.82) or radiotherapy (RT): pHR = 0.68 (95% CI: 0.50–0.93). *Conclusion.* In conclusion, the use of statins could promote the prognosis of patients with PCa, especially for postdiagnostic users. For patients who received either ADT or radical prostatectomy (RP), statin use could decrease the PCSM. As for those who received either ADT or RT, statin use could decrease the ACM.

1. Introduction

Prostate cancer (PCa) is one of the most common malignant tumors; it has the second highest incidence and is the fifth leading cause of cancer-related death in men worldwide. Approximately 1.4 million incident cases were diagnosed, which led to more than 300 thousand deaths in 2020 [1]. Although localized PCa has a high 5-year survival rate, advanced PCa usually indicates a poor prognosis [2]. Radical prostatectomy (RP) and radiotherapy (RT) are the main treatments for localized PCa, and androgen deprivation therapy (ADT) is backbone of treatment for advanced PCa. Although ADT could slow tumor progression, a clinical state called castration-resistant PCa inevitably appears after treatment for a while. However, with a better understanding of PCa and the approval of multiple new drugs, the management of advanced PCa or castration-resistant PCa will change rapidly over the next decade [3].

Statins are a type of commonly used drug and are usually used to decrease serum cholesterol levels and prevent cardiovascular diseases by inhibiting cholesterol synthesis through suppression of HMG-CoA reductase. Beyond these effects, more and more evidence suggest that statins also play a role in the treatment of cancer, including colon cancer, breast cancer, and PCa [4–6]. Laboratory studies have proved that statins could limit cancer progression by promoting cell apoptosis, inflammation, and inhibition of cancer cell proliferation, adhesion, and angiogenesis [7–10]. Moreover, our previous study revealed that statins played a significant role in decreasing the risk of biomedical recurrence (BCR) in patients with PCa after definite therapies, especially RT [11].

Previous meta-analyses have demonstrated that statin use is associated with a reduced risk of prostate cancerspecific mortality (PCSM) and all-cause mortality (ACM) in PCa patients [12, 13]. But the number of cohort studies included in previous meta-analyses is limited, and many novel studies have been conducted since their publications, and the results of these new studies were inconsistent. Therefore, this systematic review and meta-analysis was conducted and aimed to reevaluate the association between statins and outcomes such as PCSM and ACM among men with PCa. Also, we conducted a subgroup analysis to examine the differences in prognosis among patients with different primary treatments or the time of statin initiation.

2. Methods

This study was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [14]. The protocol was registered on PROSPERO (ID: CRD 42022337522).

2.1. Literature Search. A systematic search of papers from Medline (PubMed), Embase (Ovid), and Cochrane was performed from inception to April 2022 by two independent reviewers (SJX and AY); conflicts were confirmed by the third reviewer XQD and finally resolved by consensus. All cohort studies evaluating the effect of statins on prognostic outcomes in patients with PCa were available with no language limitations. The literature was searched using the following terms: ("Prostatic Neoplasms" with its free words) and ("Statin" or "Atorvastatin" or "Cerivastatin" or "Compactin" or "Fluvastatin" or "HMG-CoA" or "Lovastatin" or "Mevastatin" or "Pravastatin" or "Rosuvastati'n or "Rosvastatin" or "Simvastatin"). The detailed search strategies of Medline (PubMed), Embase (Ovid), and Cochrane are shown in Supplement 1 Tables S1A-S1C. Also, potentially relevant studies were screened out from reference lists of articles retrieved, meta-analyses, and reviews.

2.2. Inclusion and Exclusion Criteria. Research articles were included if they satisfied the following criteria: (1) the study design was a cohort study; (2) studies examined the effect of statins on clinical outcomes in patients with prostate cancer; (3) the outcomes of interest were ACM or PCSM; and (4) relevant survival data with a hazard ratio (HR) estimate and its 95% confidence intervals (CIs) were reported. Studies satisfying the following criteria were excluded: (1) a case report, review, comment, or news item; (2) animal studies; (3) *in vitro* studies; and (4) studies with duration of follow-up shorter than 6 months.

2.3. Data Extraction and Quality Assessment. After exporting all retrieved articles to EndNote X9.3.3, duplicated articles were discarded. Two reviewers (SJX and AY) selected studies that met our criteria and then checked the results. Disagreements were resolved via discussion, involving the third reviewer (XQD). The following data were extracted from eligible articles: first author, year of publication, country of origin, study design, data sources, follow-up period, definition of statin use, tumor stage, primary treatment, adjustment variables, outcome, and HRs with corresponding 95% CIs. We extracted the risk estimate adjusted for the greatest number of confounding factors when a study provided more than one risk estimate.

We used the Newcastle–Ottawa scale (NOS) tool to evaluate the quality of studies, and the score of each study is presented in Supplement 2 Table S2. A study with a score of 7 or more was regarded as high quality.

2.4. Data Synthesis and Analysis. Heterogeneity across studies was measured by the I^2 statistic and the 'Cochran's Qtest, with $I^2 > 50\%$ and the Q-test p < 0.1 indicating significant heterogeneity [15]. The pooled hazard ratio (pHR) with corresponding 95% CIs for all included studies was obtained using a random effects model. Besides, the publication bias of included studies was examined using both Begg's [16] and Egger's [17] tests and then visualized as a contour-enhanced funnel plot. Where significant publication bias existed, the trim and fill method was carried out to normalize the publication bias [18], and the normalized combined effects will be used to verify the initial conclusion. We also performed metaregression analysis to find the possible reasons responsible for heterogeneity, and we used the following parameters: publication year, median follow-up time, age, BMI value, Gleason score, PSA level, race, and tumor stage. Finally, subgroup analyses were performed stratified by primary treatment and the time of statin initiation.

We performed statistical analyses using R software version 4.1.2 and the package "meta." A P value less than 0.05 indicated statistical significance.

3. Results

3.1. Study Characteristics. A total of 1,203 citations were screened and assessed, and 24 cohort studies [19–42] were finally included in this study. The PRISMA flow diagram presented in Figure 1 shows the study selection process. Supplement 3 Table S3 shows the basic characteristics of the included studies. All the studies were published between 2010 and 2021, with at least 6 score of NOS results. Among these studies, 7 studies were conducted in the USA [20, 23, 24, 28, 37, 41, 42], 4 in Canada [21, 22, 29, 40], 4 in China [25, 26, 31, 36], 4 in Finland [19, 27, 32, 34], 1 in Italy [30], 1 in Denmark [33], 1 in Germany [35], 1 in the UK [38], and 1 in Norway [39]. 18 studies reported the association between statin use and PCMS, whereas 17 studies examined ACM.




FIGURE 1: PRISMA flowchart for study selection.

3.2. Relationship between Statin Use and PCSM. Eighteen studies with 347, 186 participants were included in the analysis of statin use and PCSM. The forest plot (Figure 2(a)) shows the overall effect of statin use on PCSM. The results suggested that statin use led to a significantly decreased risk of PCSM (pHR = 0.76, 95% CI: 0.69-0.84, $I^2 = 91\%$, random effects model). Subgroup analysis stratified by primary treatments is shown in Figure 3(a) and indicates that there is a significant reduction in PCSM among patients accepting ADT (pHR=0.69, 95% CI: 0.59-0.81, $I^2 = 89\%$), RP (pHR = 0.72, 95% CI: 0.54-0.96, $I^2 = 94\%$), or RT or RP or ADT (pHR = 0.86, 95% CI: 0.77–0.96, $I^2 = 79\%$). Surprisingly, we found there was no statistical significance between PCSM and statin use when patients were treated with RT or RP. In the subgroup analysis stratified by the initiation of statin use (Figure 3(b)), we found there existed a significant reduction in PCSM among people accepting prediagnostic statin use $(pHR = 0.86, 95\% CI: 0.75-0.99, I^2 = 73\%)$ and postdiagnostic statin use (pHR = 0.81, 95% CI: 0.77-0.85, $I^2 = 0\%$).

As the heterogeneity of the main analysis and subgroup analysis was significantly high, we performed metaregression. We constructed a univariate meta-regression model using the publication year, median follow-up time, age, BMI value, percentage of patients with a Gleason score \geq 7, race, PSA level, and percentage of patients with a tumor stage \geq T3. We found tumor stage was significantly associated with PCSM (*P* = 0.0237, see Supplement 4 Figure S1A), whereas other parameters were not significantly associated with PCSM.

Also, sensitivity analysis was performed to evaluate the effect of each study on the pHR. By stepwise excluding each study, we could observe that the overall estimates remained stable (Figure 4(a)). Both Begg's rank correlation test (z = -1.93, P = 0.0534) and Egger's linear regression test (t = 0.02, P = 0.9847) showed no evidence of significant publication bias. The contour-enhanced funnel plot showed a little asymmetry, as few studies were outside the dashed lines (Figure 4(b)). The trim and fill method estimated one study was missing due to publication bias (Figure 4(c)) and showed little evidence of publication bias. Then, we did a filled forest plot (Figure 4(d)), and the pHR was 0.74 (95% CI: 0.67-0.82, $I^2 = 91\%$, random effects model), which was consistent with our original result. The Galbraith plot showed a similar result, showing that most studies stood within the dashed lines (Figure 4(e)).

naa et al. 2021 opez et al. 2021	-0.20							
opez et al. 2021	0.20	0.0842	+-		0.82	[0.70;	0.97]	6.4
opez et ul. 2021	0.02	0.0727			1.02	[0.88;	1.18]	6.7
Iamilton et al. 2021	-0.43	0.1517			0.65	[0.48;	0.88]	4.5
ldberg et al. 2021	-0.27	0.0870			0.76	[0.64;	0.90]	6.3
Tan et al. 2020	-0.22	0.0734	+		0.80	[0.69;	0.92]	6.7
	-0.02	0.0389			0.98	[0.91;	1.06]	7.5
	-0.26	0.0562	+		0.77	[0.69;	0.86]	7.1
	-0.36	0.1537	-		0.70	[0.52;	0.95]	4.5
	-0.58	0.0316	── ¦		0.56	[0.53;	0.60]	7.6
	-0.84	0.1517			0.43	[0.32;	0.58]	4.5
	-0.17	0.0725	+-		0.84	[0.73;	0.97]	6.7
	-0.16	0.1047			0.85	[0.69;	1.04]	5.8
	-0.19	0.0369	+		0.83	[0.77;	0.89]	7.5
	-0.01	0.4876			0.99	[0.38;	2.57]	0.9
	-0.27	0.0734			0.76	[0.66;	0.88]	6.7
rtvedt Grytli et al. 2014	-0.36	0.1153	—		0.70	[0.56;	0.88]	5.5
al. 2014	-0.26	0.1721	-		0.77	[0.55;	1.08]	4.1
eybels et al. 2013	-1.66	0.5698	İ		0.19	[0.06;	0.58]	0.7
ffects model					0.76	[0.69;	0.84]	100.0
	1				7	,		
			0.1 0.5 1 2		10			
			(a)					
Study	TE	seTE	Hazard Ratio	HR	95%	-CI We	eight ((%)
A.I. Peltomaa et al. 2021	-0.17	0.0515		0.84	[0.76;	0.93]	7.5	
Robert J. Hamilton et al. 2021	-0.45			0.64			6.4	
,					-	-		
6								
Szu-Yuan Wu et al. 2019	-0.29			0.75			7.6	
Ke Li et al. 2019						-		
			+					
acob A. Gordon et al. 2018								
11					-	-		
0								
					-	-		
e								
					-	-		
					-	-		
					-	-		
Matthew S. Katz et al. 2010	-0.53	0.2379		0.59			3.3	
Dan done officiato nº - 1-1				0.74	[0.69	0.951	100.0	
				0.76	[0.68;	0.85]	100.0	
Heterogeneity: $I^2 = 96\%$, $\tau^2 = 0.046$	00, p < 0	.01	0.5 1 2	!				
	al. 2014 eybels et al. 2013 ifects model eity: $I^2 = 91\%$, $\tau^2 = 0.0316$, $p < 0.0$ itudy A.I. Peltomaa et al. 2021 Robert J. Hamilton et al. 2021 Kiang-Lin Tan et al. 2020 Abhishek Kumar et al. 2020 Abhishek Kumar et al. 2020 izu-Yuan Wu et al. 2019 ce Li et al. 2019 ndia Anderson-Carter et al. 2019 acob A. Gordon et al. 2018 isigne Benzon Larsen et al. 2016 Martin Boegemann et al. 2016 i-Min Sun et al. 2015 Driana Yu et al. 2014 Wilan S. Geybels et al. 2013 Matthew S. Katz et al. 2010 Random effects model	Kurina et al. 2020 -0.26 Wu et al. 2019 -0.36 entausta et al. 2019 -0.36 erson-Carter et al. 2019 -0.84 ordon et al. 2018 -0.17 en et al. 2018 -0.16 furtola et al. 2017 -0.19 con Larsen et al. 2016 -0.01 et al. 2014 -0.27 rtvedt Grytli et al. 2014 -0.36 al. 2014 -0.26 eybels et al. 2013 -1.66 Ffects model	Kunna et al. 2020 -0.26 0.0562 Wu et al. 2019 -0.36 0.1537 entausta et al. 2019 -0.36 0.0316 erson-Carter et al. 2019 -0.84 0.1517 ordon et al. 2018 -0.17 0.0725 en et al. 2018 -0.16 0.1047 furtola et al. 2017 -0.19 0.0369 con Larsen et al. 2016 -0.01 0.4876 et al. 2014 -0.27 0.0734 rtvedt Grytli et al. 2014 -0.36 0.1153 al. 2014 -0.26 0.1721 eybels et al. 2013 -1.66 0.5698 effects modeleity: $I^2 = 91\%$, $\tau^2 = 0.0316$, $p < 0.01$ GudyTEseTEA.I. Peltomaa et al. 2021 -0.17 0.0515 Robert J. Hamilton et al. 2020 -0.12 0.0371 Abhishek Kumar et al. 2020 -0.12 0.0371 Abhishek Kumar et al. 2019 -0.26 0.2212 ndia Anderson-Carter et al. 2019 -0.26 0.2212 ndia Anderson-Carter et al. 2019 -0.43 0.0195 acob A. Gordon et al. 2018 -0.76 0.1499 Giuseppe Di Lorenzo et al. 2018 -0.21 0.0286 Geemu Keskivaliet al. 2015 -0.43 0.0429 une M. Chan et al. 2015 -0.43 0.0429 une M. Chan et al. 2015 -0.17 0.0848 Oriana Yu et al. 2015 -0.17 0.0848 Oriana Yu et al. 2014 -0.15 0.0503 Willan S. Geybels et al. 2013 -0.12 0.2572	Admart et al. 2020 entausta et al. 2019 entausta et al. 2019 ordon et al. 2018 en et al. 2018 en et al. 2018 en et al. 2017 en et al. 2017 en et al. 2017 en et al. 2016 en et al. 2017 en et al. 2017 en et al. 2016 en et al. 2017 en et al. 2014 et al. 2013 et al. 2013 et al. 2014 et al. 2014 et al. 2013 et al. 2013 et al. 2014 et al. 2013 et al. 2014 et al. 2013 et al. 2014 et al. 2013 et al. 2021 et al. 2021 et al. 2021 et al. 2021 et al. 2021 et al. 2021 et al. 2020 et al. 2019 et al. 2016 et al. 2018 et al. 2016 et al. 2017 et al. 2014 et al. 2015 et al. 2014 et al	Attria et al. 2020 0.26 0.0562 entausta et al. 2019 -0.36 0.1537 entausta et al. 2019 -0.58 0.0316 erson-Carter et al. 2019 -0.84 0.1517 ordon et al. 2018 -0.17 0.0725 entausta et al. 2016 -0.01 0.4876 ordon Larsen et al. 2016 -0.01 0.4876 et al. 2014 -0.26 0.1721 eybels et al. 2013 -1.66 0.5698 fects model 0.17 0.0515 eity: $F = 91\%$, $\tau^2 = 0.0316$, $p < 0.01$ 0.0371 Muty TE seTE Hazard Ratio HR ALI. Peltomaa et al. 2021 -0.17 0.0515 0.84 O.1 0.5 1 2 xu-Yua Wu et al. 2020 -0.22 0.0371 0.89 Whishek Kumar et al. 2019 -0.26 0.212 0.777 ndia Anderson-Carter et al. 2019 -0.43 0.0195 0.655 acub A. Gordon et al. 2018 -0.76 0.1499 0.477 Giuseppe Di Lorenzo et al. 2016 0.88 0.288 0.448 0.44	Numar et al. 2019 -0.26 0.0562 0.77 entausta et al. 2019 -0.36 0.1537 0.70 entausta et al. 2019 -0.58 0.0316 0.56 ordon et al. 2018 -0.17 0.0725 0.84 onto at al. 2018 -0.16 0.1047 0.85 introla et al. 2017 -0.19 0.0369 0.83 ion Larsen et al. 2016 -0.01 0.4876 0.76 ittrola et al. 2014 -0.27 0.0734 0.76 ittrola et al. 2013 -1.66 0.5698 0.17 ittrola et al. 2013 -1.66 0.5698 0.76 ittrola et al. 2014 -0.26 0.1721 0.77 etitty: $l^2 = 91\%$, $r^2 = 0.0316$, $p < 0.01$ (a) 0.76 0.19 ittrola et al. 2012 -0.17 0.0515 0.84 0.76 ittrola et al. 2019 -0.26 0.2712 0.77 0.505 ittrola et al. 2019 -0.27 0.0371 0.84 0.76 ittrola et al. 2019 -0.26 0.2212 0.77 0.505 ittrola et al. 2019 -0.	$\begin{aligned} \text{Authar terms of all 2000} & -0.26 & 0.0562 & 0.77 & [0.69; \\ \text{entausta et al. 2019} & -0.36 & 0.1537 & 0.76 & [0.63]; \\ \text{erton Carter et al. 2019} & -0.58 & 0.0316 & 0.56 & [0.53]; \\ \text{ordon et al. 2018} & -0.17 & 0.0725 & 0.84 & [0.77] & 0.68]; \\ \text{furtola et al. 2017} & -0.19 & 0.0369 & 0.83 & [0.69]; \\ \text{furtola et al. 2016} & -0.01 & 0.4876 & 0.99 & [0.38]; \\ \text{et al. 2014} & -0.27 & 0.0734 & 0.77 & [0.56]; \\ \text{al. 2014} & -0.26 & 0.1721 & 0.77 & [0.56]; \\ \text{al. 2014} & -0.26 & 0.1721 & 0.77 & [0.69]; \\ \text{eity: } l^2 = 91\%, \ r^2 = 0.0316, \ p < 0.01 & 0.515 & 0.77 & [0.69]; \\ \text{facts model} \\ \text{eity: } l^2 = 91\%, \ r^2 = 0.0316, \ p < 0.01 & 0.515 & 0.70 & 0.515 \\ \text{Subsert J. Hamilton et al. 2021} & -0.17 & 0.0515 & 0.84 & [0.76]; \\ \text{Subsert J. Hamilton et al. 2021} & -0.17 & 0.0515 & 0.898 & 0.64 & [0.53]; 0.78] \\ \text{Sing-Lin Tan et al. 2020} & -0.12 & 0.0371 & 0.89 & [0.83]; 0.96] \\ \text{Whishek Kumar et al. 2020} & -0.12 & 0.0371 & 0.898 & [0.83]; 0.96] \\ \text{Whishek Kumar et al. 2019} & -0.26 & 0.2212 & 0.77 & [0.56]; 1.19] \\ \text{ndia Anderson-Carter et al. 2019} & -0.26 & 0.2212 & 0.77 & [0.68]; 0.83] & [0.68] \\ \text{Given pick berd is an et al. 2016} & -0.76 & 0.1499 & 0.474 & [0.35]; 0.63] \\ \text{Given pick berd is an et al. 2016} & -0.71 & 0.0848 & 0.77 & [0.68]; 1.69] \\ \text{facting Bernzon Larsen et al. 2016} & -0.21 & 0.0286 & 0.811 & [0.77]; 0.86] \\ \text{Fermu Keskivaliet al. 2016} & -0.21 & 0.0286 & 0.81 & [0.77]; 0.86] \\ \text{Fermu Keskivaliet al. 2016} & -0.17 & 0.0848 & 0.84 & [0.77]; 0.99] \\ \text{Jriana Yu et al. 2015} & -0.43 & 0.0429 & 0.44 & [0.27]; 0.59] \\ \text{Jrians Pick at et al. 2015} & -0.17 & 0.0513 & 0.89 & [0.53]; 0.63] \\ \text{Letrogeneity: } l^2 = 96\%, \ r^2 = 0.0400, \ p < 0.01 & 0.276 & 0.219 & 0.55 & 0.660; 0.71] \\ \text{une M. Chan et al. 2015} & -0.17 & 0.0848 & 0.84 & [0.77]; 0.99] \\ \text{Jrians Yu et al. 2014} & -0.53 & 0.2379 & 0.55 & [0.68]; 0.85] \\ \text{Letrogeneity: } l^2 = 96\%, \ r^2 = 0.0400, \ p < 0.01 & 0.55 & 0.660; 0.71] \\ \text{Matthew S. Katz et al. 2010} & -0.53 & 0.2379 & 0.55 & 0.660; 0.71]$	$\begin{aligned} \text{Attriat et al. 2020} & -0.26 & 0.0562 & 0.77 & [0.69; 0.86] \\ \text{entausta et al. 2019} & -0.36 & 0.1537 & 0.77 & [0.59; 0.86] \\ \text{ertson-Carter et al. 2019} & -0.36 & 0.1537 & 0.77 & [0.59; 0.86] \\ \text{erson-Carter et al. 2019} & -0.84 & 0.1517 & 0.77 & [0.59; 0.86] \\ \text{ordon et al. 2018} & -0.16 & 0.1047 & 0.0725 & 0.84 & [0.73; 0.97] \\ \text{furtola et al. 2017} & -0.19 & 0.0369 & 0.88 & [0.77; 0.89] \\ \text{on Larsen et al. 2016} & -0.01 & 0.4876 & 0.99 & [0.38; 2.57] \\ \text{rtvedt Grytli et al. 2014} & -0.27 & 0.0734 & 0.76 & [0.66; 0.88] \\ \text{rtvedt Grytli et al. 2013} & -1.66 & 0.5698 & 0.1153 & 0.77 & [0.55; 1.08] \\ \text{iety: } F = 91\%, r^2 = 0.0316, p < 0.01 & 0.4876 & 0.99 & 0.83; 0.67 & 77 & [0.56; 0.88] \\ \text{itty } & \text{TE} & \text{seTE} & \text{Hazard Ratio} & \text{HR} & 95\% - \text{CI Weight (} \\ \text{M.L Peltomaa et al. 2021} & -0.17 & 0.515 & 0.644 & [0.76; 0.93] & 7.5 & 0.644 & [0.53; 0.78] & 6.4 & 0.33; 0.56] & 7.75 & [0.68; 0.82] & 7.6 & 0.441 & 0.53; 0.78 & 6.4 & 0.599 & 0.371 & 0.591 & 0.644 & [0.53; 0.78] & 6.4 & 0.777 & [0.55; 1.08] & 0.77 & [0.56; 0.88] & 0.77 & [0.56; 0.88] & 0.77 & [0.56; 0.88] & 0.77 & [0.56; 0.88] & 0.77 & [0.56; 0.88] & 0.76 & [0.69; 0.84] & 0.77 & [0.56; 0.88] & 0.77 & [0.56; 0.88] & 0.76 & [0.66; 0.88] & 0.76 & [0.66; 0.88] & 0.76 & [0.66; 0.88] & 0.76 & [0.66; 0.88] & 0.76 & [0.66; 0.88] & 0.76 & [0.66; 0.88] & 0.76 & [0.66; 0.88] & 0.76 & [0.66; 0.88] & 0.76 & [0.66; 0.88] & 0.76 & [0.66; 0.88] & 0.76 & [0.66; 0.88] & 0.77 & [0.55; 1.08] & 0.77 & [0.55; 1.08] & 0.77 & [0.55; 1.08] & 0.77 & [0.55; 1.08] & 0.77 & [0.55; 0.68] & 0.77 & [0.56; 0.88] & 0.75 & [0.68; 0.82] & 7.6 & 0.77 & [0.56; 0.88] & 0.75 & [0.68; 0.82] & 7.6 & 0.77 & [0.56; 0.83] & 0.75 & [0.68; 0.82] & 7.6 & 0.77 & [0.56; 0.48] & 0.77 & [0.56; 0.48] & 0.77 & [0.56; 0.48] & 0.77 & [0.56; 0.48] & 0.77 & [0.56; 0.48] & 0.77 & [0.56; 0.48] & 0.77 & [0.56; 0.48] & 0.77 & [0.56; 0.48] & 0.77 & [0.56; 0.48] & 0.77 & [0.56; 0.48] & 0.75 & [0.68; 0.82] & 7.6 & 0.84 & [0.77; 0.86] & 7.9 & 0.65 & [0.60; 0.71] & 0.84 & 0.77 & [0.56; 0.48] &$

FIGURE 2: The effect of statins on PCSM or ACM of prostate cancer using a random effects model. (a) The forest plot for the HR of PCSM. (b) The forest plot for the HR of ACM.

3.3. Relationship between Statin Use and ACM. Seventeen studies with 246 and 167 participants were included in the analysis of statin use and ACM. As shown in the forest plot (Figure 2(b)), the result revealed a significant reduction in ACM among patients using statins (pHR = 0.76, 95% CI: 0.68–0.85, I^2 = 96%, random effects model). In the subgroup analysis by primary treatment (Figure 5(a)), patients accepting ADT (pHR = 0.72, 95% CI: 0.63–0.82, I^2 = 89%), RT (pHR = 0.68, 95% CI: 0.50–0.93, I^2 = 0%), RT or RP (pHR = 0.84, 95% CI: 0.72–0.99, I^2 = 0%), or abiraterone or enzalutamide (pHR = 0.44, 95% CI: 0.35–0.56, I^2 = 0%)

showed decreased risk of ACM, whereas the RP showed no effect on ACM. This result was not consistent with a previous study [43]. When stratified by the initiation of statin use (Figure 5(b)), only postdiagnostic statin use (pHR = 0.81, 95% CI: 0.78–0.85, $I^2 = 23\%$) was connected with a reduced risk of ACM.

A univariate meta-regression model was constructed using the parameters we mentioned above. We found the percentage of white people was associated with ACM (P = 0.0021, see Supplement 4 Figure S1B), and other parameters were not associated with ACM.

Journal of Oncology

Study	TE	seT	E	Hazard Ratio	HR	95% -CI	0
Treatment = ADT							(%)
A.I. Peltomaa et al. 2021	-0.20	0.084	42	i	0.82	[0.70; 0.97]	8.5
Robert J. Hamilton et al. 2021	-0.43				0.65	[0.48; 0.88]	
Szu-Yuan Wu et al. 2019	-0.26				0.77	[0.69; 0.86]	
India Anderson-Carter et al. 2019	-0.58			+	0.56	[0.53; 0.60]	
Helene Hartvedt Grytli et al. 2014				-	0.30		7.0
Random effects model	-0.36	0.11:	55		0.70	[0.56; 0.88] [0.59; 0.81]	
				Ŭ	0.07	[0.57, 0.01]	11.5
Heterogeneity: $I^2 = 89\%$, $\tau^2 = 0.0230$, $p < 0.01$							
Treatment = RT or RP or ADT							
Abhishek Kumar et al. 2020	-0.02	0.03	39	+	0.98	[0.91; 1.06]	10.5
Teemu J. Murtola et al. 2017	-0.16	0.104	47		0.85	[0.69; 1.04]	7.5
Signe Benzon Larsen et al. 2016	-0.19	0.03	59	+	0.83	[0.77; 0.89]	10.5
Oriana Yu et al. 2014	-0.27	0.073	34	÷.	0.76	[0.66; 0.88]	9.0
Random effects model				\diamond	0.86	[0.77; 0.96]	37.5
Heterogeneity: $I^2 = 79\%$, $\tau^2 = 0.0096$, $p < 0.01$							
Treatment = RP							
Roni M. Joentausta et al. 2019	-0.36	0.15	37		0.70	[0.52; 0.95]	5.4
Teemu Keskivaliet al. 2016	-0.01	0.482	76		0.99	[0.38; 2.57]	1.0
Random effects model				\diamond	0.72	[0.54; 0.96]	6.4
Heterogeneity: $I^2 = 0\%$, $\tau^2 = 0$, $p < 0.50$					0.72	[0.0 1, 0.90]	0.1
Treatment = RT or RP							
Yu-An Chen et al. 2018	-0.17	0.072	25		0.84	[0.73; 0.97]	9.1
Milan S. Geybels et al. 2013	-1.66			Ī	0.19	[0.06; 0.58]	0.7
Random effects model	1.00	0.00			0.44	[0.11; 1.88]	9.8
Heterogeneity: $I^2 = 85\%$, $\tau^2 = 0.9397$, $p < 0.01$							
Treatment = RT							
J.Caon et al. 2014	-0.26	0.172	21		0.77	[0.55; 1.08]	4.8
Random effects model				•	0.76	[0.69; 0.84]	100.0
Heterogeneity: $I^2 = 91\%$, $\tau^2 = 0.0224$, $p < 0.01$			Г				
Test for subgroup differences $\chi_4^2 = 5.98$, df = 4			0.1	0.5 1 2 10			
$(p = 0.20)$ $n_{1} = n_{4}$							
			(a)				
Study		TE	seTE	Hazard Ratio	HR	95% -CI	Weight
Statin = post-diagnosis				9			(%)
A.I. Peltomaa et al. 2021	-	0.20	0.0842		0.82	[0.70; 0.97]	8.7
Szu-Yuan Wu et al. 2019			0.0562		0.77	[0.69; 0.86]	12.7
Roni M. Joentausta et al. (post-diagnosis) 2019			0.1097	-	0.83	[0.67; 1.03]	6.2
Teemu J. Murtola et al. (post-diagnosis) 2017			0.1047	-	0.85	[0.67, 1.03] [0.69; 1.04]	6.6
Signe Benzon Larsen et al. (2016			0.0369	+	0.83	[0.09, 1.04] [0.77; 0.89]	16.1
Oriana Yu et al. 2014			0.0734	10 + + 17	0.83	[0.66; 0.88]	10.1
J.Caon et al. 2014			0.1721		0.77	[0.55; 1.08]	3.1
Random effects model					0.81	[0.77; 0.85]	63.3
Heterogeneity: $I^2 = 0\%$, $\tau^2 = 0$, $p = 0.88$							
Statin = pre-diagnosis							
Abhishek Kumar et al. 2020	-	0.02	0.0389	i	0.98	[0.91; 1.06]	15.7
Roni M. Joentausta et al. (post-diagnosis) 2019	-	0.36	0.1537	- 	0.70	[0.52; 0.95]	3.7
Yu-An Chen et al. 2018	-	0.17	0.0725	i	0.84	[0.73; 0.97]	10.2
Teemu J. Murtola et al. (post-diagnosis) 2017	-	0.08	0.1023	\	0.92	[0.75; 1.12]	6.8
Milan S. Geybels et al. 2013	-	1.66).5698 ·		0.19	[0.06; 0.58]	0.3
Random effects model				\blacklozenge	0.86	[0.75; 0.99]	36.7
Heterogeneity: $I^2 = 73\%$, $\tau^2 = 0.012$, $p < 0.01$							
Random effects model				•	0.83	[0.78; 0.89]	100.0
Heterogeneity: $I^2 = 62\%$, $\tau^2 = 0.0053$, $p < 0.01$					1 0.00	[
Test for subgroup differences: $\chi_4^2 = 0.82$, df = 1	(p = 0.3)	37)		0.1 0.5 1 2 1	0		
C I 7/4	-	·					

(b)

FIGURE 3: (a) The forest plot for the HR of PCSM with subgroup analysis by primary treatments. (b) The forest plot for the HR of PCSM with subgroup analysis by the initiation of statin use.




FIGURE 4: Sensitivity analysis and the detection of publication bias for included studies on the HR of the PCSM. (a) Sensitivity analysis by stepwise excluding the included studies. (b) The funnel plot. (c) The trim and fill funnel plot. (d) The filled forest plot. (e) The Galbraith plot. Effect sizes as *z*-scores plotted as a function of the inverse standard error for each study reported in the present study. The middle line is the line of best fit, while the upper and lower dashed lines represent the upper and lower 95% confidence limits.

Sensitivity analysis was presented in Supplement 4, Figure S2A, and the overall estimates remained stable after excluding each study. The contour-enhanced funnel plot (Supplement 4, Figure S2B) did not show good symmety, where some studies stood outside the dashed lines. However, both Begg's test (z = 0.25, P = 0.8048) and Egger's test

(t = -0.75, P = 0.4647) showed no evidence of statistically significant publication bias. The trim and fill method was carried out, and it was estimated that two studies were missing due to publication bias (Supplement 4 Figure S2C). The filled forest plot (Supplement 4 Figure S2D) was carried out with pHR = 0.81 (95% CI: 0.70–0.93, $I^2 = 95\%$, random

Journal of Oncology

Study						
	TE	seTE	Hazard Ratio	HR	95% -CI	Weight (%)
Treatment = ADT						(/0)
A.I. Peltomaa et al. 2021	-0.12	7 0.0515		0.84	[0.76; 0.93]	9.8
Robert J. Hamilton et al. 2021	-0.4	5 0.0986	i	0.64		8.6
Szu-Yuan Wu et al. 2019					[0.53; 0.78]	
	-0.2			0.75	[0.68; 0.82]	9.9
ndia Anderson-Carter et al. 2019	-0.43	3 0.0195	E i i i	0.65	[0.63; 0.68]	10.3
andom effects model			\Leftrightarrow	0.72	[0.63; 0.82]	38.5
Heterogeneity: $I^2 = 89\%$, $\tau^2 = 0.0134$, $p < 0.0$)1					
Freatment = RT or RP or ADT						
Abhishek Kumar et al. 2020	0.02	2 0.0176		1.02	[0.99; 1.06]	10.3
igne Benzon Larsen et al. 2016	-0.2	1 0.0286	+	0.81	[0.77; 0.86]	10.2
andom effects model				0.91	[0.73; 1.14]	20.4
leterogeneity: $I^2 = 98\%$, $\tau^2 = 0.0260$, $p < 0.0$)1			0.91	[0.73, 1.14]	20.1
reatment = RT						
Le li et al. 2019	-0.20	6 0.2212		0.77	[0.50; 1.19]	5.1
fatthew S. Katz et al. 2010	-0.5			0.59	[0.37; 0.94]	4.8
andom effects model	0.0			0.39	[0.57; 0.94]	4.0 9.9
leterogeneity: $I^2 = 0\%$, $\tau^2 = 0$, $p < 0.41$				0.08	[0.30; 0.93]	2.7
reatment = Abitaterone or Enzalutamide	-0.7	6 0.1499		0.47	[0 35.0 62]	71
acob A. Gordon et al. 2018				0.47	[0.35; 0.63]	7.1
Giuseppe Di Lorenzo et al. 2018	-0.92	2 0.1994		0.40	[0.27; 0.59]	5.7
andom effects model				0.44	[0.35; 0.56]	12.7
Heterogeneity: $I^2 = 0\%$, $\tau^2 = 0$, $p = 0.52$						
reatment = RP						
eemu Keskivaliet al. 2016	0.08	0.2285		1.08	[0.69; 1.69]	5.0
reatment = RP or RP						
une M. Chan et al. 2015	-0.12	7 0.0848	++	0.84	[0.71; 0.99]	9.0
Ailan S. Geybels et al. 2013	-0.12	2 0.2572		0.89	[0.54; 1.47]	4.4
Random effects model			\diamond	0.84	[0.72; 0.99]	13.4
Heterogeneity: $I^2 = 0\%$, $\tau^2 = 0$, $p = 0.83$						
ieterogenentyri evo, v evp evee						
Random effects model				0.73	[0.64; 0.84]	100.0
			~			
				0170	[0101; 0101]	100.0
Heterogeneity: $I^2 = 96\%$, $\tau^2 = 0.0486$, $p < 0.0$	5 = 5 (p = 0)).01)	0.5 1 2	0170	[0101, 0101]	100.0
Heterogeneity: $I^2 = 96\%$, $\tau^2 = 0.0486$, $p < 0.0$ lest for subgroup differences: $\chi_5^2 = 27.38$, df	f = 5 (p = 0)).01)	0.5 1 2 (a)	0.00		100.0
Heterogeneity: $I^2 = 96\%$, $\tau^2 = 0.0486$, $p < 0.0$ 'est for subgroup differences: $\chi_5^2 = 27.38$, df	F = 5 (p = 0)TE).01) seTE		HR	95% -CI	Weight
Heterogeneity: $I^2 = 96\%$, $\tau^2 = 0.0486$, $p < 0.0$ est for subgroup differences: $\chi_5^2 = 27.38$, df Study	f = 5 (p = 0)		(a)			
Heterogeneity: $I^2 = 96\%$, $\tau^2 = 0.0486$, $p < 0.0$ est for subgroup differences: $\chi_5^2 = 27.38$, df Study Statin = post-diagnosis	T = 5 (p = 0 TE	seTE	(a) Hazard Ratio	HR	95% -CI	Weight (%)
Ieterogeneity: $I^2 = 96\%$, $\tau^2 = 0.0486$, $p < 0.0$ est for subgroup differences: $\chi_5^2 = 27.38$, df Study Statin = post-diagnosis A.I. Peltomaa et al. 2021	TE -0.17	seTE 0.0515	(a) Hazard Ratio	HR 0.84	95% -CI [0.76; 0.93]	Weight (%) 13.1
Ieterogeneity: $l^2 = 96\%$, $\tau^2 = 0.0486$, $p < 0.0$ est for subgroup differences: $\chi_5^2 = 27.38$, df Study statin = post-diagnosis A.I. Peltomaa et al. 2021 szu-Yuan Wu et al. 2019	TE -0.17 -0.29	seTE 0.0515 0.0478	(a) Hazard Ratio	HR 0.84 0.75	95% -CI [0.76; 0.93] [0.68; 0.82]	Weight (%) 13.1 13.3
Teterogeneity: $I^2 = 96\%$, $\tau^2 = 0.0486$, $p < 0.0$ est for subgroup differences: $\chi_5^2 = 27.38$, df Study tatin = post-diagnosis A.I. Peltomaa et al. 2021 zu-Yuan Wu et al. 2019 igne Benzon Larsen et al. 2016	TE -0.17 -0.29 -0.21	seTE 0.0515 0.0478 0.0286	(a) Hazard Ratio	HR 0.84 0.75 0.81	95% -CI [0.76; 0.93] [0.68; 0.82] [0.77; 0.86]	Weight (%) 13.1 13.3 14.4
Ieterogeneity: $I^2 = 96\%$, $\tau^2 = 0.0486$, $p < 0.0$ est for subgroup differences: $\chi_5^2 = 27.38$, df Study A.I. Peltomaa et al. 2021 Szu-Yuan Wu et al. 2019 Signe Benzon Larsen et al. 2016 une M. Chan et al. 2015	TE -0.17 -0.29	seTE 0.0515 0.0478 0.0286 0.0848	(a) Hazard Ratio	HR 0.84 0.75	95% -CI [0.76; 0.93] [0.68; 0.82]	Weight (%) 13.1 13.3
Ieterogeneity: $I^2 = 96\%$, $\tau^2 = 0.0486$, $p < 0.0$ est for subgroup differences: $\chi_5^2 = 27.38$, df Study A.I. Peltomaa et al. 2021 Szu-Yuan Wu et al. 2019 Signe Benzon Larsen et al. 2016 une M. Chan et al. 2015	TE -0.17 -0.29 -0.21	seTE 0.0515 0.0478 0.0286	(a) Hazard Ratio	HR 0.84 0.75 0.81	95% -CI [0.76; 0.93] [0.68; 0.82] [0.77; 0.86]	Weight (%) 13.1 13.3 14.4
Ieterogeneity: $I^2 = 96\%$, $\tau^2 = 0.0486$, $p < 0.0$ est for subgroup differences: $\chi_5^2 = 27.38$, df Study Statin = post-diagnosis A.I. Peltomaa et al. 2021 Szu-Yuan Wu et al. 2019 Signe Benzon Larsen et al. 2016 une M. Chan et al. 2015 Driana Yu et al. 2014	-0.17 -0.29 -0.21 -0.17	seTE 0.0515 0.0478 0.0286 0.0848	(a) Hazard Ratio	HR 0.84 0.75 0.81 0.84	95% -CI [0.76; 0.93] [0.68; 0.82] [0.77; 0.86] [0.71; 0.99] [0.78; 0.95]	Weight (%) 13.1 13.3 14.4 10.8
Ieterogeneity: $I^2 = 96\%$, $\tau^2 = 0.0486$, $p < 0.0$ est for subgroup differences: $\chi_5^2 = 27.38$, df Study Statin = post-diagnosis A.I. Peltomaa et al. 2021 Szu-Yuan Wu et al. 2019 Signe Benzon Larsen et al. 2016 une M. Chan et al. 2015 Driana Yu et al. 2014 Matthew S. Katz et al. 2010	-0.17 -0.29 -0.21 -0.17 -0.15	seTE 0.0515 0.0478 0.0286 0.0848 0.0503	(a) Hazard Ratio	HR 0.84 0.75 0.81 0.84 0.86 0.59	95% -CI [0.76; 0.93] [0.68; 0.82] [0.77; 0.86] [0.71; 0.99] [0.78; 0.95] [0.37; 0.94]	Weight (%) 13.1 13.3 14.4 10.8 13.2 3.7
Ieterogeneity: $I^2 = 96\%$, $\tau^2 = 0.0486$, $p < 0.0$ est for subgroup differences: $\chi_5^2 = 27.38$, df Study diatin = post-diagnosis A.I. Peltomaa et al. 2021 izu-Yuan Wu et al. 2019 digne Benzon Larsen et al. 2016 une M. Chan et al. 2015 Driana Yu et al. 2014 Matthew S. Katz et al. 2010 Random effects model	-0.17 -0.29 -0.21 -0.17 -0.15 -0.53	seTE 0.0515 0.0478 0.0286 0.0848 0.0503	(a) Hazard Ratio	HR 0.84 0.75 0.81 0.84 0.86	95% -CI [0.76; 0.93] [0.68; 0.82] [0.77; 0.86] [0.71; 0.99] [0.78; 0.95]	Weight (%) 13.1 13.3 14.4 10.8 13.2
Ieterogeneity: $I^2 = 96\%$, $\tau^2 = 0.0486$, $p < 0.0$ est for subgroup differences: $\chi_5^2 = 27.38$, df Study Statin = post-diagnosis A.I. Peltomaa et al. 2021 Szu-Yuan Wu et al. 2019 Signe Benzon Larsen et al. 2016 une M. Chan et al. 2015 Driana Yu et al. 2014 Matthew S. Katz et al. 2010 Random effects model -Ieterogeneity: $I^2 = 23\%$, $\tau^2 = 0.0003$, $p < 0.2$	-0.17 -0.29 -0.21 -0.17 -0.15 -0.53	seTE 0.0515 0.0478 0.0286 0.0848 0.0503	(a) Hazard Ratio	HR 0.84 0.75 0.81 0.84 0.86 0.59	95% -CI [0.76; 0.93] [0.68; 0.82] [0.77; 0.86] [0.71; 0.99] [0.78; 0.95] [0.37; 0.94]	Weight (%) 13.1 13.3 14.4 10.8 13.2 3.7
Heterogeneity: $I^2 = 96\%$, $\tau^2 = 0.0486$, $p < 0.0$ cest for subgroup differences: $\chi_5^2 = 27.38$, df Study Statin = post-diagnosis A.I. Peltomaa et al. 2021 Szu-Yuan Wu et al. 2019 Signe Benzon Larsen et al. 2016 'une M. Chan et al. 2015 Driana Yu et al. 2014 Matthew S. Katz et al. 2010 Random effects model Heterogeneity: $I^2 = 23\%$, $\tau^2 = 0.0003$, $p < 0.2$ Statin = pre-diagnosis	-0.17 -0.29 -0.21 -0.17 -0.15 -0.53	seTE 0.0515 0.0478 0.0286 0.0848 0.0503 0.2379 —	(a) Hazard Ratio	HR 0.84 0.75 0.81 0.84 0.86 0.59 0.81	95% -CI [0.76; 0.93] [0.68; 0.82] [0.77; 0.86] [0.71; 0.99] [0.78; 0.95] [0.37; 0.94] [0.78; 0.85]	Weight (%) 13.1 13.3 14.4 10.8 13.2 3.7 68.4
Ieterogeneity: $I^2 = 96\%$, $\tau^2 = 0.0486$, $p < 0.0$ est for subgroup differences: $\chi_5^2 = 27.38$, df Study statin = post-diagnosis A.I. Peltomaa et al. 2021 izu-Yuan Wu et al. 2019 signe Benzon Larsen et al. 2016 une M. Chan et al. 2015 Driana Yu et al. 2014 Matthew S. Katz et al. 2010 Random effects model Heterogeneity: $I^2 = 23\%$, $\tau^2 = 0.0003$, $p < 0.2$ Statin = pre-diagnosis Abhishek Kumar et al. 2020	-0.17 -0.29 -0.21 -0.17 -0.53 26 0.02	seTE 0.0515 0.0478 0.0286 0.0848 0.0503 0.2379 —	(a) Hazard Ratio	HR 0.84 0.75 0.81 0.84 0.86 0.59 0.81	95% -CI [0.76; 0.93] [0.68; 0.82] [0.77; 0.86] [0.71; 0.99] [0.78; 0.95] [0.37; 0.94] [0.78; 0.85]	Weight (%) 13.1 13.3 14.4 10.8 13.2 3.7
Ieterogeneity: $I^2 = 96\%$, $\tau^2 = 0.0486$, $p < 0.0$ est for subgroup differences: $\chi_5^2 = 27.38$, df Study statin = post-diagnosis A.I. Peltomaa et al. 2021 izu-Yuan Wu et al. 2019 signe Benzon Larsen et al. 2016 une M. Chan et al. 2015 Driana Yu et al. 2014 Matthew S. Katz et al. 2010 Random effects model Heterogeneity: $I^2 = 23\%$, $\tau^2 = 0.0003$, $p < 0.2$ Statin = pre-diagnosis Abhishek Kumar et al. 2020	-0.17 -0.29 -0.21 -0.17 -0.15 -0.53	seTE 0.0515 0.0478 0.0286 0.0848 0.0503 0.2379 —	(a) Hazard Ratio	HR 0.84 0.75 0.81 0.84 0.86 0.59 0.81	95% -CI [0.76; 0.93] [0.68; 0.82] [0.77; 0.86] [0.71; 0.99] [0.78; 0.95] [0.37; 0.94] [0.78; 0.85]	Weight (%) 13.1 13.3 14.4 10.8 13.2 3.7 68.4
Ieterogeneity: $I^2 = 96\%$, $\tau^2 = 0.0486$, $p < 0.0$ est for subgroup differences: $\chi_5^2 = 27.38$, df Study statin = post-diagnosis A.I. Peltomaa et al. 2021 izu-Yuan Wu et al. 2019 signe Benzon Larsen et al. 2016 une M. Chan et al. 2015 Driana Yu et al. 2014 Matthew S. Katz et al. 2010 Random effects model Heterogeneity: $I^2 = 23\%$, $\tau^2 = 0.0003$, $p < 0.2$ statin = pre-diagnosis Abhishek Kumar et al. 2020 .i-Min Sun et al. 2015	-0.17 -0.29 -0.21 -0.17 -0.53 26 0.02	seTE 0.0515 0.0478 0.0286 0.0848 0.0503 0.2379 —	(a) Hazard Ratio	HR 0.84 0.75 0.81 0.84 0.86 0.59 0.81	95% -CI [0.76; 0.93] [0.68; 0.82] [0.77; 0.86] [0.71; 0.99] [0.78; 0.95] [0.37; 0.94] [0.78; 0.85]	Weight (%) 13.1 13.3 14.4 10.8 13.2 3.7 68.4 14.7
Ieterogeneity: $I^2 = 96\%$, $\tau^2 = 0.0486$, $p < 0.0$ est for subgroup differences: $\chi_5^2 = 27.38$, df Study statin = post-diagnosis A.I. Peltomaa et al. 2021 izu-Yuan Wu et al. 2019 signe Benzon Larsen et al. 2016 une M. Chan et al. 2015 Driana Yu et al. 2014 Matthew S. Katz et al. 2010 Random effects model Heterogeneity: $I^2 = 23\%$, $\tau^2 = 0.0003$, $p < 0.2$ statin = pre-diagnosis Abhishek Kumar et al. 2020 .i-Min Sun et al. 2015 Milan S. Geybels et al. 2013	-0.17 -0.29 -0.21 -0.17 -0.53 26 0.02 -0.43	seTE 0.0515 0.0478 0.0286 0.0848 0.0503 0.2379 —	(a) Hazard Ratio	HR 0.84 0.75 0.81 0.84 0.86 0.59 0.81 1.02 0.65 0.89	95% -CI [0.76; 0.93] [0.68; 0.82] [0.77; 0.86] [0.71; 0.99] [0.78; 0.95] [0.37; 0.94] [0.78; 0.85] [0.99; 1.06] [0.60; 0.71] [0.54; 1.47]	Weight (%) 13.1 13.3 14.4 10.8 13.2 3.7 68.4 14.7 13.6 3.3
Ieterogeneity: $I^2 = 96\%$, $\tau^2 = 0.0486$, $p < 0.0$ cest for subgroup differences: $\chi_5^2 = 27.38$, df Study Statin = post-diagnosis A.I. Peltomaa et al. 2021 Szu-Yuan Wu et al. 2019 Signe Benzon Larsen et al. 2016 une M. Chan et al. 2015 Driana Yu et al. 2014 Matthew S. Katz et al. 2010 Random effects model Heterogeneity: $I^2 = 23\%$, $\tau^2 = 0.0003$, $p < 0.2$ Statin = pre-diagnosis Abhishek Kumar et al. 2020 Li-Min Sun et al. 2015 Milan S. Geybels et al. 2013 Random effects model	-0.17 -0.29 -0.21 -0.17 -0.15 -0.53 26 0.02 -0.43 -0.12	seTE 0.0515 0.0478 0.0286 0.0848 0.0503 0.2379 —	(a) Hazard Ratio	HR 0.84 0.75 0.81 0.84 0.86 0.59 0.81 1.02 0.65	95% -CI [0.76; 0.93] [0.68; 0.82] [0.77; 0.86] [0.71; 0.99] [0.78; 0.95] [0.37; 0.94] [0.78; 0.85] [0.99; 1.06] [0.60; 0.71]	Weight (%) 13.1 13.3 14.4 10.8 13.2 3.7 68.4 14.7 13.6
Heterogeneity: $I^2 = 96\%$, $\tau^2 = 0.0486$, $p < 0.0$ cest for subgroup differences: $\chi_5^2 = 27.38$, df Study Statin = post-diagnosis A.I. Peltomaa et al. 2021 Szu-Yuan Wu et al. 2019 Signe Benzon Larsen et al. 2016 une M. Chan et al. 2015 Driana Yu et al. 2014 Matthew S. Katz et al. 2010 Random effects model Heterogeneity: $I^2 = 23\%$, $\tau^2 = 0.0003$, $p < 0.2$ Statin = pre-diagnosis Abhishek Kumar et al. 2020 Li-Min Sun et al. 2015 Milan S. Geybels et al. 2013 Random effects model Heterogeneity: $I^2 = 98\%$, $\tau^2 = 0.0634$, $p < 0.0$	-0.17 -0.29 -0.21 -0.17 -0.15 -0.53 26 0.02 -0.43 -0.12	seTE 0.0515 0.0478 0.0286 0.0848 0.0503 0.2379 —	(a) Hazard Ratio	HR 0.84 0.75 0.81 0.84 0.86 0.59 0.81 1.02 0.65 0.89 0.83	95% -CI [0.76; 0.93] [0.68; 0.82] [0.77; 0.86] [0.77; 0.99] [0.78; 0.95] [0.37; 0.94] [0.78; 0.85] [0.99; 1.06] [0.60; 0.71] [0.54; 1.47] [0.61; 1.14]	Weight (%) 13.1 13.3 14.4 10.8 13.2 3.7 68.4 14.7 13.6 3.3 31.6
Heterogeneity: $I^2 = 96\%$, $\tau^2 = 0.0486$, $p < 0.0$ Cest for subgroup differences: $\chi_5^2 = 27.38$, df Study Statin = post-diagnosis A.I. Peltomaa et al. 2021 Szu-Yuan Wu et al. 2019 Signe Benzon Larsen et al. 2016 lune M. Chan et al. 2015 Driana Yu et al. 2014 Matthew S. Katz et al. 2010 Random effects model Heterogeneity: $I^2 = 23\%$, $\tau^2 = 0.0003$, $p < 0.2$ Statin = pre-diagnosis Abhishek Kumar et al. 2020 Li-Min Sun et al. 2015 Milan S. Geybels et al. 2013 Random effects model Heterogeneity: $I^2 = 98\%$, $\tau^2 = 0.0634$, $p < 0.6$ Random effects model	F = 5 (p = 0) TE -0.17 -0.29 -0.21 -0.17 -0.15 -0.53 26 0.02 -0.43 -0.12 $D1$	seTE 0.0515 0.0478 0.0286 0.0848 0.0503 0.2379 —	(a) Hazard Ratio	HR 0.84 0.75 0.81 0.84 0.86 0.59 0.81 1.02 0.65 0.89	95% -CI [0.76; 0.93] [0.68; 0.82] [0.77; 0.86] [0.71; 0.99] [0.78; 0.95] [0.37; 0.94] [0.78; 0.85] [0.99; 1.06] [0.60; 0.71] [0.54; 1.47]	Weight (%) 13.1 13.3 14.4 10.8 13.2 3.7 68.4 14.7 13.6 3.3
Heterogeneity: $I^2 = 96\%$, $\tau^2 = 0.0486$, $p < 0.0$ Fest for subgroup differences: $\chi_5^2 = 27.38$, df Study Statin = post-diagnosis A.I. Peltomaa et al. 2021 Szu-Yuan Wu et al. 2019 Signe Benzon Larsen et al. 2016 June M. Chan et al. 2015 Oriana Yu et al. 2014 Matthew S. Katz et al. 2010 Random effects model Heterogeneity: $I^2 = 23\%$, $\tau^2 = 0.0003$, $p < 0.2$ Statin = pre-diagnosis Abhishek Kumar et al. 2020 Li-Min Sun et al. 2015 Milan S. Geybels et al. 2013 Random effects model Heterogeneity: $I^2 = 98\%$, $\tau^2 = 0.0634$, $p < 0.0$ Random effects model Heterogeneity: $I^2 = 94\%$, $\tau^2 = 0.0183$, $p < 0.0$	F = 5 (p = 0) TE -0.17 -0.29 -0.21 -0.17 -0.15 -0.53 26 0.02 -0.43 -0.12 $D1$ $D1$	seTE 0.0515 0.0478 0.0286 0.0848 0.0503 0.2379 —	(a) Hazard Ratio	HR 0.84 0.75 0.81 0.84 0.86 0.59 0.81 1.02 0.65 0.89 0.83	95% -CI [0.76; 0.93] [0.68; 0.82] [0.77; 0.86] [0.77; 0.99] [0.78; 0.95] [0.37; 0.94] [0.78; 0.85] [0.99; 1.06] [0.60; 0.71] [0.54; 1.47] [0.61; 1.14]	Weight (%) 13.1 13.3 14.4 10.8 13.2 3.7 68.4 14.7 13.6 3.3 31.6
Heterogeneity: $I^2 = 96\%$, $\tau^2 = 0.0486$, $p < 0.0$ Cest for subgroup differences: $\chi_5^2 = 27.38$, df Study Statin = post-diagnosis A.I. Peltomaa et al. 2021 Szu-Yuan Wu et al. 2019 Signe Benzon Larsen et al. 2016 lune M. Chan et al. 2015 Driana Yu et al. 2014 Matthew S. Katz et al. 2010 Random effects model Heterogeneity: $I^2 = 23\%$, $\tau^2 = 0.0003$, $p < 0.2$ Statin = pre-diagnosis Abhishek Kumar et al. 2020 Li-Min Sun et al. 2015 Milan S. Geybels et al. 2013 Random effects model Heterogeneity: $I^2 = 98\%$, $\tau^2 = 0.0634$, $p < 0.6$ Random effects model	F = 5 (p = 0) TE -0.17 -0.29 -0.21 -0.17 -0.15 -0.53 26 0.02 -0.43 -0.12 $D1$ $D1$	seTE 0.0515 0.0478 0.0286 0.0848 0.0503 0.2379 —	(a) Hazard Ratio	HR 0.84 0.75 0.81 0.84 0.86 0.59 0.81 1.02 0.65 0.89 0.83	95% -CI [0.76; 0.93] [0.68; 0.82] [0.77; 0.86] [0.77; 0.99] [0.78; 0.95] [0.37; 0.94] [0.78; 0.85] [0.99; 1.06] [0.60; 0.71] [0.54; 1.47] [0.61; 1.14]	Weight (%) 13.1 13.3 14.4 10.8 13.2 3.7 68.4 14.7 13.6 3.3 31.6

FIGURE 5: (a) The forest plot for the HR of ACM with subgroup analysis by primary treatments. (b) The forest plot for the HR of ACM with subgroup analysis by the initiation of statin use.

effects model), which indicated the reliability of our metaanalysis. The Galbraith plot also showed a similar result, showing that a few studies stood outside the dashed lines (Supplement 4 Figure S2E).

4. Discussion

This meta-analysis involving 24 studies with 369, 206 individuals reinvestigated the relationship between statin use and outcomes in patients with PCa and evaluated whether statin use contributed to different clinical outcomes when patients accepted different primary treatments. Our previous study has provided evidence that statins could reduce the risk of BCR in patients with PCa. However, the previous study focused on BCR and ignored other clinical outcomes; also, the study did not distinguish prediagnostic statin users from postdiagnostic users. Therefore, we conducted this meta-analysis to further evaluate the relationship between statins and clinical outcomes and instruct clinical medication. Our results revealed that statin use was associated with a significant reduction of PCSM and ACM. Subgroup analyses by primary treatment and initiation of statins were conducted. For PCSM, patients accepting ADT, RP, or RT or ADT, RP could benefit from statins. However, subgroups including ADT showed significant heterogeneity, which indicated individuals may not always benefit from statins when accepting ADT. Consistent with previous studies [13], our results demonstrated both postdiagnostic and prediagnostic statin users could obtain a reduced risk of PCSM. However, the prediagnostic statin use group showed high heterogeneity ($I^2 = 73\%$), indicating this result may not be suitable for all patients. As for ACM, patients accepting ADT, RT or RP, RT, abiraterone or enzalutamide showed potential benefits from statin use, where the ADT subgroup also had high heterogeneity. Although our study showed statin use did not reduce ACM for patients treated with RP, the number of studies in this subgroup was too limited, and further investigation was needed. In the subgroup analysis of ACM, we included two studies that used abiraterone or enzalutamide as the primary treatment. The result revealed statin use may reduce the risk of ACM when accepting abiraterone or enzalutamide, which was consistent with previous meta-analyses [44]. As the selection of primary treatment depends on certain subtypes of PCa, the patients involved in these two studies were all diagnosed with metastatic castration-resistant prostate cancer (mCRPC). Therefore, our study suggested that patients with mCRPC might benefit from statins when treated with abiraterone or enzalutamide. In 2016, an in vitro study discovered that statins could promote the therapeutic effect of enzalutamide in androgen-sensitive LNCaP and VCaP cells [45]. More randomized controlled trials and further studies are needed to clarify the effect of statins on enzalutamide use.

Additionally, we found only postdiagnostic statin use was associated with decreased risk of ACM but not prediagnosis. Alexandre et al. have pointed out [46] that prediagnostic statin users are more likely to be smokers, overweight, older, and have associated cardiovascular diseases or other diseases that might lead to a poor prognosis. Anyway, we observed a decreased risk of PCSM and ACM among patients accepting postdiagnostic statin use. Our findings could help to instruct clinical medication in patients with PCa.

Despite the fact that the antitumor effect of statins has been reported for years, many unknowns remain about their antitumor mechanisms, especially for PCa. It is known that statins can decrease cholesterol synthesis by suppressing HMG-CoA reductase. The presence of PCa was reported to be tightly related to cholesterol accumulation in prostatic tissues [47]. PCa could abnormally accumulate cholesterol by affecting the ABCA1 promoter [48] and activating the PI3K-AKT-mTOR signaling pathway [49]. Statins could suppress tumor growth by breaking the cholesterol balance in prostatic tissues. Cholesterol is a precursor for androgen synthesis, and androgen is essential for the initiation and progression of PCa. Therefore, it is not difficult to understand that statins could suppress androgen synthesis and improve the effect of ADT. This is in accordance with our results that statins could improve prognosis of patients with PCa when treated with ADT. Additionally, it was reported that statins competitively reduced the uptake of dehydroepiandrosterone sulfate, thus inhibiting the tumor's androgen synthesis [50].

However, there are limitations to this study. First, most included studies did not provide the baseline serum cholesterol levels. As statins are prescribed to decrease cholesterol levels, the serum cholesterol level might be a potential confounder in the analysis. Second, the definition of statin use varied among the included studies. The types of statins, doses of statins, initiation time of statin use, and duration of statin use were various or not complete in the included studies. The differences among these factors may lead to heterogeneity. Third, some patients received more than one kind of treatment, which could influence the result of subgroup analysis when stratified by primary treatment. Fourth, although most results of studies have been adjusted for important covariates, those unadjusted factors might have an impact on the results of individual studies.

5. Conclusion

In conclusion, the use of statins is beneficial for ACM and PCSM, especially for postdiagnostic users. For patients who received either ADT or RP, statin use could decrease the PCSM. As for those who accepted either ADT or RT, statin use could decrease ACM. However, for patients accepting ADT, statin use may not always be beneficial for them. In future studies, prospective studies or large-sample randomized controlled trials are needed to further elucidate the effects and specific mechanisms of statins in PCa.

Data Availability

All the data analyzed in this study are included within article/supplementary material and are available from the corresponding authors upon request.

Disclosure

Ye An and Jian-Xuan Sun are the co-first authors.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors' Contributions

HHL, SJX, HJ, and WSG contributed to research question selection; AY, SJX, and XQD searched the literature, selected the studies, and collected the included studies' information. AY performed the meta-analysis and wrote the manuscript. LCQ, ZXY, XMY, and XJZ revised the manuscript. Ye An and Jian-Xuan contributed equally to this work.

Acknowledgments

The authors thank all the R package developers. This research was supported by the National Natural Science Foundation of China (81772729).

Supplementary Materials

Supplement 1: Details of the search strategy to retrieve the studies. Supplement 2: Newcastle–Ottawa scale for assessing the quality of studies in meta-analysis. Supplement 3: Characteristics of included studies in the systematic review and meta-analysis. Supplement 4: Meta-regression and sensitivity analysis. (*Supplementary Materials*)

References

- H. Sung, J. Ferlay, R. L. Siegel et al., "Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries," *CA: a cancer journal for clinicians*, vol. 71, no. 3, pp. 209–249, 2021.
- [2] R. L. Siegel, K. D. Miller, and A. Jemal, "Cancer statistics, 2018," CA: a cancer journal for clinicians, vol. 68, no. 1, pp. 7–30, 2018.
- [3] U. Swami, T. R. McFarland, R. Nussenzveig, and N. Agarwal, "Advanced prostate cancer: treatment advances and future directions," *Trends in cancer*, vol. 6, no. 8, pp. 702–715, 2020.
- [4] M. R. Graaf, A. B. Beiderbeck, A. C. Egberts, D. J. Richel, and H. J. Guchelaar, "The risk of cancer in users of statins," *Journal* of Clinical Oncology, vol. 22, no. 12, pp. 2388–2394, 2004.
- [5] J. N. Poynter, S. B. Gruber, P. D. Higgins et al., "Statins and the risk of colorectal cancer," *New England Journal of Medicine*, vol. 352, no. 21, pp. 2184–2192, 2005.
- [6] E. A. Platz, M. F. Leitzmann, K. Visvanathan et al., "Statin drugs and risk of advanced prostate cancer," *Journal of the National Cancer Institute*, vol. 98, no. 24, pp. 1819–1825, 2006.
- [7] C. Wang, W. Tao, Y. Wang et al., "Rosuvastatin, identified from a zebrafish chemical genetic screen for antiangiogenic compounds, suppresses the growth of prostate cancer," *European Urology*, vol. 58, no. 3, pp. 418–426, 2010.
- [8] L. L. Bañez, J. C. Klink, J. Jayachandran et al., "Association between statins and prostate tumor inflammatory infiltrate in men undergoing radical prostatectomy. Cancer epidemiology, biomarkers & prevention : a publication of the American

Association for Cancer Research," Cancer Epidemiology, Biomarkers & Prevention, vol. 19, no. 3, pp. 722–728, 2010.

- [9] J. Wu, W. W. L. Wong, F. Khosravi, M. D. Minden, and L. Z. Penn, "Blocking the Raf/MEK/ERK pathway sensitizes acute myelogenous leukemia cells to lovastatin-induced apoptosis," *Cancer Research*, vol. 64, no. 18, pp. 6461–6468, 2004.
- [10] T. Nübel, W. Dippold, H. Kleinert, B. Kaina, and G. Fritz, "Lovastatin inhibits Rho-regulated expression of E-selectin by TNF-α and attenuates tumor cell adhesion," *The FASEB Journal*, vol. 18, no. 1, pp. 140–142, 2004.
- [11] J. X. Sun, C. Q. Liu, X. Y. Zhong et al., "Statin use and the risk of prostate cancer biochemical recurrence following definitive therapy: a systematic review and meta-analysis of cohort studies," *Frontiers in oncology*, vol. 12, Article ID 887854, 2022.
- [12] Z. Mei, M. Liang, L. Li, Y. Zhang, Q. Wang, and W. Yang, "Effects of statins on cancer mortality and progression: a systematic review and meta-analysis of 95 cohorts including 1, 111, 407 individuals," *International Journal of Cancer*, vol. 140, no. 5, pp. 1068–1081, 2017.
- [13] S. Zhong, X. Zhang, L. Chen, T. Ma, J. Tang, and J. Zhao, "Statin use and mortality in cancer patients: systematic review and meta-analysis of observational studies," *Cancer Treatment Reviews*, vol. 41, no. 6, pp. 554–567, 2015.
- [14] L. Shamseer, D. Moher, M. Clarke et al., "Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation," *BMJ*, vol. 349, no. 1, p. g7647, 2015.
- [15] L. V. Hedges and T. D. Pigott, "The power of statistical tests in meta-analysis," *Psychological Methods*, vol. 6, no. 3, pp. 203–217, 2001.
- [16] C. B. Begg and M. Mazumdar, "Operating characteristics of a rank correlation test for publication bias," *Biometrics*, vol. 50, no. 4, pp. 1088–1101, 1994.
- [17] M. Egger, G. D. Smith, M. Schneider, and C. Minder, "Bias in meta-analysis detected by a simple, graphical test," *BMJ*, vol. 315, no. 7109, pp. 629–634, 1997.
- [18] S. Duval and R. Tweedie, "Trim and fill: a simple funnel-plotbased method of testing and adjusting for publication bias in meta-analysis," *Biometrics*, vol. 56, no. 2, pp. 455–463, 2000.
- [19] A. I. Peltomaa, P. Raittinen, K. Talala et al., "Prostate cancer prognosis after initiation of androgen deprivation therapy among statin users. A population-based cohort study," *Prostate Cancer and Prostatic Diseases*, vol. 24, no. 3, pp. 917–924, 2021.
- [20] D. S. Lopez, D. Huang, K. K. Tsilidis et al., "The role of testosterone replacement therapy and statin use, and their combination, in prostate cancer," *Cancer Causes & Control*, vol. 32, no. 9, pp. 965–976, 2021.
- [21] R. J. Hamilton, K. Ding, J. M. Crook et al., "The association between statin use and outcomes in patients initiating androgen deprivation therapy," *European Urology*, vol. 79, no. 4, pp. 446–452, 2021.
- [22] H. Goldberg, F. K. Mohsin, R. Saskin et al., "The suggested unique association between the various statin subgroups and prostate cancer," *European Urology Focus*, vol. 7, no. 3, pp. 537–545, 2021.
- [23] X. L. Tan, Y. Lin, T. R. Rebbeck et al., "Individual and joint effects of metformin and statins on mortality among patients with high-risk prostate cancer," *Cancer Medicine*, vol. 9, no. 7, pp. 2379–2389, 2020.
- [24] A. Kumar, P. Riviere, E. Luterstein et al., "Associations among statins, preventive care, and prostate cancer mortality,"

Prostate Cancer and Prostatic Diseases, vol. 23, no. 3, pp. 475-485, 2020.

- [25] S. Y. Wu, S. C. Fang, H. J. Shih, Y. C. Wen, and Y. H. J. Shao, "Mortality associated with statins in men with advanced prostate cancer treated with androgen deprivation therapy," *European Journal of Cancer*, vol. 112, pp. 109–117, 2019.
- [26] K. Li, J. Si-Tu, J. Qiu et al., "Statin and metformin therapy in prostate cancer patients with hyperlipidemia who underwent radiotherapy: a population-based cohort study," *Cancer Management and Research*, vol. 11, pp. 1189–1197, 2019.
- [27] R. M. Joentausta, A. Rannikko, and T. J. Murtola, "Prostate cancer survival among statin users after prostatectomy in a Finnish nationwide cohort," *The Prostate*, vol. 79, no. 6, pp. 583–591, 2019.
- [28] I. Anderson-Carter, N. Posielski, J. I. Liou et al., "The impact of statins in combination with androgen deprivation therapyin patients with advanced prostate cancer: a large observational study," *Urologic Oncology: Seminars and Original Investigations*, vol. 37, no. 2, pp. 130–137, 2019.
- [29] J. A. Gordon, C. Buonerba, G. Pond et al., "Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure: the international retrospective observational STABEN study," *Oncotarget*, vol. 9, no. 28, pp. 19861–19873, 2018.
- [30] G. Di Lorenzo, G. Sonpavde, G. Pond et al., "Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate," *European Urology Focus*, vol. 4, no. 6, pp. 874–879, 2018.
- [31] Y. A. Chen, Y. J. Lin, C. L. Lin et al., "Simvastatin therapy for drug repositioning to reduce the risk of prostate cancer mortality in patients with hyperlipidemia," *Frontiers in Pharmacology*, vol. 9, p. 225, 2018.
- [32] T. J. Murtola, A. I. Peltomaa, K. Talala et al., "Statin use and prostate cancer survival in the Finnish randomized study of screening for prostate cancer," *European Urology Focus*, vol. 3, no. 2-3, pp. 212–220, 2017.
- [33] S. B. Larsen, C. Dehlendorff, C. Skriver et al., "Postdiagnosis statin use and mortality in Danish patients with prostate cancer," *Journal of Clinical Oncology*, vol. 35, no. 29, pp. 3290–3297, 2017.
- [34] T. Keskivali, P. Kujala, T. Visakorpi, T. L. J. Tammela, and T. J. Murtola, "Statin use and risk of disease recurrence and death after radical prostatectomy," *The Prostate*, vol. 76, no. 5, pp. 469–478, 2016.
- [35] M. Boegemann, K. Schlack, A. K. Fischer et al., "Influence of statins on survival outcome in patients with metastatic castration resistant prostate cancer treated with abiraterone acetate," *PLoS One*, vol. 11, no. 9, Article ID e0161959, 2016.
- [36] L. M. Sun, M. C. Lin, C. L. Lin et al., "Statin use reduces prostate cancer all-cause mortality: a nationwide populationbased cohort study," *Medicine (Baltimore)*, vol. 94, no. 39, Article ID e1644, 2015.
- [37] J. M. Chan, S. A. Kenfield, A. Paciorek, E. A. Platz, E. L. Giovannucci, and M. J. Stampfer, "Postdiagnostic statin use and the risk of lethal prostate cancer in the health professionals follow-up study," *Cancer Epidemiology, Biomarkers* & Prevention, vol. 24, no. 10, pp. 1638–1640, 2015.
- [38] O. Yu, M. Eberg, S. Benayoun et al., "Use of statins and the risk of death in patients with prostate cancer," *Journal of Clinical Oncology*, vol. 32, no. 1, pp. 5–11, 2014.
- [39] H. H. Grytli, M. W. Fagerland, S. D. Fosså, and K. A. Taskén, "Association between use of β -blockers and prostate cancerspecific survival: a cohort study of 3561 prostate cancer

patients with high-risk or metastatic disease," *European Urology*, vol. 65, no. 3, pp. 635–641, 2014.

- [40] J. Caon, M. Paquette, J. Hamm, and T. Pickles, "Does statin or ASA affect survival when prostate cancer is treated with external beam radiation therapy?" *Prostate Cancer*, vol. 2014, Article ID 184297, 6 pages, 2014.
- [41] M. S. Geybels, J. L. Wright, S. K. Holt, S. Kolb, Z. Feng, and J. L. Stanford, "Statin use in relation to prostate cancer outcomes in a population-based patient cohort study," *The Prostate*, vol. 73, no. 11, pp. 1214–1222, 2013.
- [42] M. S. Katz, P. R. Carroll, J. E. Cowan, J. M. Chan, and A. V. D'Amico, "Association of statin and nonsteroidal antiinflammatory drug use with prostate cancer outcomes: results from CaPSURE," *BJU International*, vol. 106, no. 5, pp. 627–632, 2010.
- [43] A. D. Raval, D. Thakker, H. Negi, A. Vyas, M. W. Salkini, and M. W. Salkini, "Association between statins and clinical outcomes among men with prostate cancer: a systematic review and meta-analysis," *Prostate Cancer and Prostatic Diseases*, vol. 19, no. 2, pp. 151–162, 2016.
- [44] A. M. Joshua, A. Armstrong, M. Crumbaker et al., "Statin and metformin use and outcomes in patients with castrationresistant prostate cancer treated with enzalutamide: A meta-analysis of AFFIRM, PREVAIL and PROSPER," *European journal of cancer*, vol. 170, pp. 285–295, 2022.
- [45] H. Syvälä, P. Pennanen, M. Bläuer, T. L. Tammela, and T. J. Murtola, "Additive inhibitory effects of simvastatin and enzalutamide on androgen-sensitive LNCaP and VCaP prostate cancer cells," *Biochemical and Biophysical Research Communications*, vol. 481, no. 1-2, pp. 46–50, 2016.
- [46] L. Alexandre, A. B. Clark, H. Y. Bhutta, S. S. Chan, M. P. Lewis, and A. R. Hart, "Association between statin use after diagnosis of esophageal cancer and survival: a population-based cohort study," *Gastroenterology*, vol. 150, no. 4, pp. 854–865.e1, 2016.
- [47] C. P. Schaffner, "Prostatic cholesterol metabolism: regulation and alteration," *Progress in clinical and biological research*, vol. 75a, pp. 279–324, 1981.
- [48] B. H. Lee, M. G. Taylor, P. Robinet et al., "Dysregulation of cholesterol homeostasis in human prostate cancer through loss of ABCA1," *Cancer Research*, vol. 73, no. 3, pp. 1211–1218, 2013.
- [49] S. Yue, J. Li, S. Y. Lee et al., "Cholesteryl ester accumulation induced by PTEN loss and PI3K/AKT activation underlies human prostate cancer aggressiveness," *Cell Metabolism*, vol. 19, no. 3, pp. 393–406, 2014.
- [50] L. C. Harshman, X. Wang, M. Nakabayashi et al., "Statin use at the time of initiation of androgen deprivation therapy and time to progression in patients with hormone-sensitive prostate cancer," *JAMA Oncology*, vol. 1, no. 4, pp. 495– 504, 2015.